Thallium-201SPECT Assessment in the Detection of Recurrences of Treated Gliomas and Ependymomas

Overview

Journal Clin Transl Oncol

Specialty Oncology

Date 2006 Nov 1

PMID 17074674

Citations 2

Authors

Ana Paula Caresia

Joan Castell-Conesa

Montserra Negre

Antoni Mestre

Gemma Cuberas

Anabel Manes

Xavier Maldonado

Affiliations

Soon will be listed here.

Abstract

Introduction: The aim of this study was to establish the value of thalium-(201) single-photon emission computed tomography ((201)Tl-SPECT) in the detection of recurrences in the follow-up of patients with treated primary neuroepithelial tumours.

Material And Methods: Sixty-three (201)Tl-SPECT were performed in 36 patients with glioma (12 males, mean age of 46 +/- 13 years). All patients underwent surgery and adjuvant radiotherapy (and some of them received chemotherapy). All patients were submitted to morphological neuroimaging techniques as well (and (201) Tl-SPECT). Mean follow-up was 18.3 +/- 14.6 months. Gold standard was based on clinical follow-up, therapeutical decisions (at least 4 months after (201)Tl-SPECT) and imaging features.

Results: Sensitivity and specificity of (201)Tl-SPECT to detect glioma recurrences were 90% and 100% respectively and 93% accuracy. Sensitivity and specificity for high grade tumours, were 100% respectively. Due to 4 false negatives, sensitivity and specificity for low grade gliomas were 78% and 100%. In the positive (201)Tl-SPECT group of patients overall survival was 13.64% at the end of the study. The negative (201)Tl-SPECT group had 84.62% overall survival at the end of the study (p = 0.0003). CONCLUSIONS. (201)Tl-SPECT is a valuable and noninvasive diagnostic procedure to detect recurrence or progression disease for treated gliomas and ependymomas. (201)Tl-SPECT has a good correlation with short term prognosis with excellent diagnostic accuracy.

Citing Articles

Progress on the diagnosis and evaluation of brain tumors.

Gao H, Jiang X Cancer Imaging. 2013; 13(4):466-81.

PMID: 24334439 PMC: 3864167. DOI: 10.1102/1470-7330.2013.0039.

CT-based quantitative SPECT for the radionuclide ²⁰¹Tl: experimental validation and a standardized uptake value for brain tumour patients.

Willowson K, Bailey D, Schembri G, Baldock C Cancer Imaging. 2012; 12:31-40.

PMID: 22375306 PMC: 3335331. DOI: 10.1102/1470-7330.2012.0005.

References

Datta N, Pasricha R, Gambhir S, Prasad S, Phadke R . Comparative evaluation of 201Tl SPECT and CT in the follow-up of irradiated brain tumors. Int J Clin Oncol. 2004; 9(1):51-8. DOI: 10.1007/s10147-003-0362-4. View

Martinez del Valle Torres M, Gomez Rio M, Rodriguez Fernandez A, Sabatel Hernandez G, Ortega Lozano S, Ramos Font C . [Value of thallium 201-SPECT in typing brain space-occupying lesions]. Rev Esp Med Nucl. 2004; 23(5):330-7. DOI: 10.1016/s0212-6982(04)72312-5. View

Brunetti A, Alfano B, Soricelli A, Tedeschi E, Mainolfi C, Covelli E . Functional characterization of brain tumors: an overview of the potential clinical value. Nucl Med Biol. 1996; 23(6):699-715. DOI: 10.1016/0969-8051(96)00069-8. View

Higa T, Maetani S, Yoichiro K, Nabeshima S . TI-201 SPECT compared with histopathologic grade in the prognostic assessment of cerebral gliomas. Clin Nucl Med. 2001; 26(2):119-24. DOI: 10.1097/00003072-200102000-00006. View

Katano H, Karasawa K, Sugiyama N, Yamashita N, Ohkura A, Watanabe K . Comparison of thallium-201 uptake and retention indices for evaluation of brain lesions with SPECT. J Clin Neurosci. 2003; 9(6):653-8. DOI: 10.1054/jocn.2002.1142. View

Nagamachi S, Jinnouchi S, Nabeshima K, Nishii R, Flores 2nd L, Kodama T . The correlation between 99mTc-MIBI uptake and MIB-1 as a nuclear proliferation marker in glioma--a comparative study with 201Tl. Neuroradiology. 2002; 43(12):1023-30. DOI: 10.1007/s002340100629. View

Benard F, Romsa J, Hustinx R . Imaging gliomas with positron emission tomography and single-photon emission computed tomography. Semin Nucl Med. 2003; 33(2):148-62. DOI: 10.1053/snuc.2003.127304. View

Matheja P, Rickert C, Weckesser M, Palkovic S, Lottgen J, Riemann B . Sequential scintigraphic strategy for the differentiation of brain tumours. Eur J Nucl Med. 2000; 27(5):550-8. DOI: 10.1007/s002590050542. View

Sun D, Liu Q, Liu W, Hu W . Clinical application of 201Tl SPECT imaging of brain tumors. J Nucl Med. 2000; 41(1):5-10. View

10.

Taki S, Kakuda K, Kakuma K, Kobayashi K, Ohashi M, Ito S . 201Tl SPET in the differential diagnosis of brain tumours. Nucl Med Commun. 1999; 20(7):637-45. DOI: 10.1097/00006231-199907000-00007. View

11.

Beauchesne P, Pedeux R, Boniol M, Soler C . 99mTc-sestamibi brain SPECT after chemoradiotherapy is prognostic of survival in patients with high-grade glioma. J Nucl Med. 2004; 45(3):409-13. View

12.

Van Laere K, Ceyssens S, Van Calenbergh F, de Groot T, Menten J, Flamen P . Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value. Eur J Nucl Med Mol Imaging. 2004; 32(1):39-51. DOI: 10.1007/s00259-004-1564-3. View

13.

Hoffman S, Propp J, McCarthy B . Temporal trends in incidence of primary brain tumors in the United States, 1985-1999. Neuro Oncol. 2006; 8(1):27-37. PMC: 1871920. DOI: 10.1215/S1522851705000323. View

14.

Vos M, Berkhof J, Postma T, Hoekstra O, Barkhof F, Heimans J . Thallium-201 SPECT: the optimal prediction of response in glioma therapy. Eur J Nucl Med Mol Imaging. 2005; 33(2):222-7. DOI: 10.1007/s00259-005-1883-z. View

15.

Sasaki M, Kuwabara Y, Yoshida T, Nakagawa M, Fukumura T, Mihara F . A comparative study of thallium-201 SPET, carbon-11 methionine PET and fluorine-18 fluorodeoxyglucose PET for the differentiation of astrocytic tumours. Eur J Nucl Med. 1998; 25(9):1261-9. DOI: 10.1007/s002590050294. View

16.

Karim A, Afra D, Cornu P, Bleehan N, Schraub S, De Witte O . Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council study BRO4: an interim analysis. Int J Radiat Oncol Biol Phys. 2002; 52(2):316-24. DOI: 10.1016/s0360-3016(01)02692-x. View

17.

Stupp R, Mason W, van den Bent M, Weller M, Fisher B, Taphoorn M . Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352(10):987-96. DOI: 10.1056/NEJMoa043330. View

18.

Vos M, Hoekstra O, Barkhof F, Berkhof J, Heimans J, van Groeningen C . Thallium-201 single-photon emission computed tomography as an early predictor of outcome in recurrent glioma. J Clin Oncol. 2003; 21(19):3559-65. DOI: 10.1200/JCO.2003.01.001. View